SELECT-CHOICE: Upadacitinib vs Abatacept in Patients With Rheumatoid Arthritis With Inadequate Response or Intolerance to bDMARDs

June 3-6, 2020; Virtual Meeting
At 12 weeks, change in DAS28-CRP with upadacitinib was noninferior to (primary endpoint) and also superior to (secondary endpoint) abatacept. Upadacitinib was also associated with superior rate of clinical remission (DAS28-CRP < 2.6).
Format: Microsoft PowerPoint (.ppt)
File Size: 197 KB
Released: August 17, 2020


Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley

Supported by an educational grant from
AbbVie Inc.
Gilead Sciences, Inc.

Related Content

Pooled analysis of filgotinib trials in rheumatoid arthritis presented at ACR 2020 finds low incidence of VTE and MACE regardless of dose, by CCO

Released: November 13, 2020

ACR 2020: ARCTIC REWIND on flare risk of TNF inhibitor taper and withdrawal among patients with rheumatoid arthritis (RA) and stable remission, as reported by CCO

Released: November 13, 2020

CCO highlights from Stanley Cohen, Sheetal Desai, Eric Ruderman on JAKs before and after DMARD failure, treat-to-target, shared decision making

Stanley B. Cohen, MD Sheetal Desai, MD, MSEd Eric M. Ruderman, MD Released: November 13, 2020

ACR 2020: SEAM-RA trial on switch to ETN or MTX monotherapy vs continued combination therapy in RA patients with stable remission, as reported by CCO

Released: November 12, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.